See Which Of The Latest 13F Filers Holds PFE

Analysis of recent 13F filings reveals that hedge funds decreased their aggregate holdings of Pfizer (PFE) by approximately 1.69%, a reduction of 62,784,187 shares, between December 31, 2024, and March 31, 2025; while some funds increased their positions, others reduced or initiated new positions, with Jones Financial Companies Lllp increasing their PFE position by 690,259 shares while Legal & General Group Plc decreased their position by 153,979 shares. The top three holders of PFE as of March 31, 2025, were Vanguard Group Inc., BlackRock Inc., and State Street Corp.

Analysis

Recent 13F filings for the period ending March 31, 2025, indicate a net reduction in institutional ownership of Pfizer Inc. (PFE). Across all reporting funds, aggregate holdings decreased by 62,784,187 shares, representing a 1.69% decline from 3,713,536,364 shares at December 31, 2024, to 3,650,752,177 shares. This trend is somewhat nuanced when examining a specific batch of the 20 most recent filers, where 14 funds held PFE. Within this smaller sample, there was a net increase of 1,059,911 shares; however, the aggregate market value of these holdings decreased by $148.681 million. This divergence suggests that either the shares added were at a lower average cost basis, existing holdings depreciated, or significant high-value disposals occurred, such as Quaker Wealth Management LLC's position change which accounted for a $100.138 million reduction in market value. For instance, while Jones Financial Companies Lllp increased its PFE position by 690,259 shares (+$14.999 million market value), and Vista Cima Wealth Management LLC initiated a new position of 500,000 shares, other funds like Rhumbline Advisers reduced holdings by 213,511 shares (-$16.922 million market value). Legal & General Group Plc also reported an increase of 153,979 shares but saw a market value decrease of $40.017 million for its PFE holding, further underscoring potential share price pressure during the quarter. Despite these shifts, major holders such as Vanguard Group Inc., BlackRock Inc., and State Street Corp maintained substantial positions. The overall sentiment signal for PFE is moderately negative (-0.35), aligning with the observed aggregate institutional selling. It is important to note that 13F filings only disclose long positions and do not capture potential short interests, thus providing an incomplete picture of a fund's total exposure or sentiment.

Key Decisions for Investors

• Investors should exercise caution regarding Pfizer, given the aggregate 1.69% reduction in institutional shareholdings during Q1 2025, which signals a broader cooling of sentiment among fund managers.
• The observed decrease in market value despite an increase in share count within a specific sample of recent filers suggests potential PFE share price weakness in Q1 2025; further investigation into the stock's valuation and recent performance is merited.
• While large index-tracking institutions remain significant holders, the net selling activity from the wider fund universe warrants a thorough review of Pfizer's current fundamentals, drug pipeline, and competitive landscape before committing new capital.
• Consider that 13F filings are backward-looking and reflect only long positions; supplement this flow data with real-time market information and qualitative company-specific research to form a comprehensive investment thesis.